{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:14:26Z","timestamp":1792725266383,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.108963","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T19:20:16Z","timestamp":1655493616000},"page":"108963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Anti-IL-17A ssDNA aptamer ameliorated psoriasis skin lesions in the imiquimod-induced psoriasis mouse model"],"prefix":"10.1016","volume":"110","author":[{"given":"Saeideh Sadat","family":"Shobeiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MohammadAli","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safoora","family":"Pordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navideh","family":"Haghnnavaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Dashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0602-6431","authenticated-orcid":false,"given":"Mojtaba","family":"Sankian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2022.108963_b0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/1744666X.2020.1713754","article-title":"Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis","volume":"16","author":"Esposito","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108963_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14712598.2019.1555235","article-title":"Anti-IL17 therapies for psoriasis","volume":"19","author":"Silfvast-Kaiser","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2022.108963_b0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5114\/reum.2019.86426","article-title":"Risankizumab in the treatment of psoriasis\u2013literature review","volume":"57","author":"Banaszczyk","year":"2019","journal-title":"Reumatologia"},{"key":"10.1016\/j.intimp.2022.108963_b0020","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.108963_b0025","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum. Vaccin Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2022.108963_b0030","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.intimp.2022.108963_b0035","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.108963_b0040","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3389\/fimmu.2018.01549","article-title":"The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis","volume":"9","author":"Albanesi","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108963_b0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.108963_b0050","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1346-8138.2011.01483.x","article-title":"Antimicrobial peptides in the pathogenesis of psoriasis","volume":"39","author":"Morizane","year":"2012","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2022.108963_b0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fphar.2017.00125","article-title":"East Indian sandalwood oil (EISO) alleviates inflammatory and proliferative pathologies of psoriasis","volume":"8","author":"Sharma","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.108963_b0060","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.2147\/DDDT.S167149","article-title":"Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis","volume":"12","author":"Haugh","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2022.108963_b0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40257-015-0162-4","article-title":"Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"17","author":"Canavan","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2022.108963_b0070","article-title":"Anti-cytokine therapy for psoriasis-not only TNF-\u03b1 blockers. Overview of reports on the effectiveness of therapy with IL-12\/IL-23 and T and B lymphocyte inhibitors","volume":"70","author":"Wcis\u0142o-Dziadecka","year":"2016","journal-title":"Adv. Hygiene Experim. Med.\/Postepy Higieny i Medycyny Doswiadczalnej"},{"key":"10.1016\/j.intimp.2022.108963_b0075","doi-asserted-by":"crossref","first-page":"212570","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"issue":"11","key":"10.1016\/j.intimp.2022.108963_b0080","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","article-title":"Anti IL-17 in psoriasis","volume":"15","author":"Ly","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.108963_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108326","article-title":"Plaque-type psoriasis inhibitors","volume":"101","author":"Shobeiri","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108963_b0090","first-page":"p. BE01","article-title":"Aptamers in therapeutics","volume":"10","author":"Parashar","year":"2016","journal-title":"J. Clin. Diagn. Res.: JCDR"},{"issue":"1","key":"10.1016\/j.intimp.2022.108963_b0095","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10753-016-0477-1","article-title":"Aptamers against pro-and anti-inflammatory cytokines: a review","volume":"40","author":"Boshtam","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2022.108963_b0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fimmu.2019.00857","article-title":"Antimicrobial peptide LL-37 facilitates intracellular uptake of RNA aptamer Apt 21\u20132 without inducing an inflammatory or interferon response","volume":"10","author":"Macleod","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108963_b0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-021-00401-3","article-title":"Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist","volume":"22","author":"Li","year":"2021","journal-title":"BMC Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108963_b0110","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108963_b0115","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im0109s01","article-title":"Removal of Lymphoid Organs","volume":"1","author":"Reeves","year":"1992","journal-title":"Curr. Protocols Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108963_b0120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/pharmaceutics12090789","article-title":"Advanced characterization of imiquimod-induced psoriasis-like mouse model","volume":"12","author":"Jabeen","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2022.108963_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106215","article-title":"Bruton\u2019s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23\/IL-17A in innate immune cells","volume":"80","author":"Nadeem","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108963_b0130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.phrs.2015.06.001","article-title":"Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC\/IL-17A pathway modulation","volume":"99","author":"Nadeem","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2022.108963_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173088","article-title":"Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells","volume":"877","author":"Al-Harbi","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2022.108963_b0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.02.014","article-title":"GPR43 activation enhances psoriasis-like inflammation through epidermal upregulation of IL-6 and dual oxidase 2 signaling in a murine model","volume":"33","author":"Nadeem","year":"2017","journal-title":"Cell. Signal."},{"issue":"7","key":"10.1016\/j.intimp.2022.108963_b0145","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2014.98","article-title":"IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing \u03b3\u03b4 T cells","volume":"134","author":"Yoshiki","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108963_b0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108963_b0155","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108963_b0160","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00403-020-02056-3","article-title":"Small molecules under development for psoriasis: on the road to the individualized therapies","volume":"312","author":"Claudia","year":"2020","journal-title":"Arch. Dermatol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.108963_b0165","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4049\/jimmunol.2000087","article-title":"Deletion of S100a8 and S100a9 enhances skin hyperplasia and promotes the Th17 response in imiquimod-induced psoriasis","volume":"206","author":"Defr\u00eane","year":"2021","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108963_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1939","article-title":"The S100A8\/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis","volume":"8","author":"Sunahori","year":"2006","journal-title":"Arthr. Res. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2022.108963_b0175","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ijc.28725","article-title":"S100A9 has a protective role in inflammation-induced skin carcinogenesis","volume":"135","author":"McNeill","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"suppl 2","key":"10.1016\/j.intimp.2022.108963_b0180","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Annals Rheumatic Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.108963_b0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.30108","article-title":"Therapeutic potential of anti\u2013interleukin-17A aptamer: Suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models","volume":"63","author":"Ishiguro","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.intimp.2022.108963_b0190","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.biochi.2011.04.003","article-title":"Antagonistic RNA aptamer specific to a heterodimeric form of human interleukin-17A\/F","volume":"93","author":"Adachi","year":"2011","journal-title":"Biochimie"},{"key":"10.1016\/j.intimp.2022.108963_b0195","doi-asserted-by":"crossref","first-page":"122188","DOI":"10.1016\/j.talanta.2021.122188","article-title":"A review of aptamer-based SERS biosensors: Design strategies and applications","volume":"227","author":"Muhammad","year":"2021","journal-title":"Talanta"},{"key":"10.1016\/j.intimp.2022.108963_b0200","unstructured":"S. Mahil, et al., Comparing the efficacy and tolerability of biologic therapies in psoriasis."},{"issue":"9","key":"10.1016\/j.intimp.2022.108963_b0205","doi-asserted-by":"crossref","DOI":"10.5070\/D3249041420","article-title":"The successful treatment with ixekizumab in a multi-failure psoriasis patient","volume":"24","author":"Azevedo","year":"2018","journal-title":"Dermatol. Online J."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:51:45Z","timestamp":1761587505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922004477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":41,"alternative-id":["S1567576922004477"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108963","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-IL-17A ssDNA aptamer ameliorated psoriasis skin lesions in the imiquimod-induced psoriasis mouse model","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108963"}}